Kolon TissueGene, Inc. (KOSDAQ:950160)

South Korea · Delayed Price · Currency is KRW

97,400

+2,100 (2.20%)

Jun 29, 2026, 3:30 PM KST

134.70% (1Y)

Market Cap	8.27T +149.6%
Revenue (ttm)	5.28B +2.9%
Net Income	-286.63B
EPS	-3,456.66
Shares Out	84.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,279
Open	98,000
Previous Close	95,300
Day's Range	89,600 - 102,300
52-Week Range	35,800 - 149,000
Beta	-0.57
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 29

Stock Exchange KOSDAQ

Ticker Symbol 950160

Full Company Profile

Financial Performance

In 2025, Kolon TissueGene's revenue was 5.16 billion, an increase of 1.68% compared to the previous year's 5.07 billion. Losses were -192.59 billion, 469.8% more than in 2024.

Financial Statements